Scholars@Duke
Paul Langlie Martin

Paul Langlie Martin

Professor Emeritus of Pediatrics
Pediatrics, Transplant and Cellular Therapy
paul.martin@duke.edu
Box 102502 Med Ctr, Durham, NC 27710
2400 Pratt St, North Pavilion; Room 8045, Durham, NC 27705

Scholarly Works - Conferences

An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel

Conference Blood · November 5, 2024 Introduction: Lovo-cel gene addition therapy, which consists of transplantation of autologous hematopoietic stem and progenitor cells (HSPCs) transduced with the BB305 lentiviral vector ( ... Full text Cite

Critical Care Support in Infants Post-Allogeneic HCT: Large Single-Center Cohort Experience

Conference Blood · November 5, 2024 IntroductionAllogeneic hematopoietic cell transplantation (HCT) is a potentially life-saving treatment for various diseases observed in childhood but m ... Full text Cite

Cultured Thymus Tissue Implantation for Congenital Athymia Post FDA Approval: Auto-Immunity and Novel Genetic Mutations

Conference Blood · November 5, 2024 IntroductionCongenital athymiais an ultra-rare cellular immune deficiency characterized by absent T cell thymic emigrants, significant T cell dysfuncti ... Full text Cite

Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Conference Blood · November 5, 2021 AbstractBackground: Tisagenlecleucel is an autologous CD19-directed T-cell immunotherapy indicated in the USA for treatment of patients up to 25 years (y) of age with B-cell ALL that is refractory or in seco ... Full text Cite

Anaerobic Antibiotics and the Risk of Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Conference Blood · November 13, 2019 Background: The gut microbiota interacts extensively with the host immune system and thus may modify the risk of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). During the post-transplant neutropeni ... Full text Cite

Outcomes of Umbilical Cord Blood Transplantation in Children with Batten Disease

Conference BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION · March 2019 Link to item Cite

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

Conference Blood · November 29, 2018 AbstractBACKGROUNDTisagenlecleucel is an FDA approved chimeric antigen receptor (CAR)-T cell therapy that reprograms T cells to eliminate CD19+ B cells. ELIANA (NCT02435849) ... Full text Cite

Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.

Conference Cancer Cell · May 14, 2018 Somatic genetic alterations of IKZF1, which encodes the lymphoid transcription factor IKAROS, are common in high-risk B-progenitor acute lymphoblastic leukemia (ALL) and are associated with poor prognosis. Such alterations result in the acquisition of stem ... Full text Link to item Cite

Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Conference Blood · December 2, 2016 AbstractA single-center trial of CD19 directed, lentiviral transduced chimeric antigen receptor (CAR) T cells (CTL019) for relapsed and refractory (r/r) B-ALL pediatric patients show ... Full text Cite

Successful Engraftment of Donor Umbilical Cord Blood (UCB) Cells after Co-Transplantation of Nicord® (Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Pediatric Patients with Severe Sickle Cell Disease

Conference Blood · December 2, 2016 AbstractBackground: Patients with severe sickle cell disease (SCD) experience organ damage, poor quality of life, and are at high risk of premature mortality. To date, allogeneic hematopoietic stem cell tran ... Full text Cite

Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

Conference Leukemia · February 2015 The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low di ... Full text Link to item Cite

Unrelated Umbilical Cord Blood Transplant for Diamond-Blackfan Anemia

Conference Biology of Blood and Marrow Transplantation · February 2014 Full text Cite

Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations

Conference Blood · November 16, 2012 AbstractAbstract 877Genetic predisposition to childhood acute lymphoblastic leukemia (ALL) is compellingly evidenced by recent genome-wide association studies (GWAS) identify ... Full text Cite

Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia

Conference Blood · November 16, 2012 AbstractAbstract 878Introduction:Treatment outcome of childhood acute lymphoblastic leukemia (ALL) ha ... Full text Cite

A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.

Conference Blood · November 16, 2012 AbstractAbstract 2466High-dose methotrexate (HDMTX) is an important element of chemotherapy for acute lymphoblastic leukemia (ALL) and other malignancies. Methotrexate cleara ... Full text Cite

Caregivers Helping in Relieving Pain – C.H.I.R.P. Project

Conference Biology of Blood and Marrow Transplantation · February 2011 Full text Cite

UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANT FOR HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)

Conference BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION · February 1, 2008 Link to item Cite

A Phase 3 Randomized, Historically-Controlled Clinical Trial Investigating the Use of Defibrotide in the Treatment of Severe Veno-Occlusive Disease Post-SCT: A Novel Approach to the Validation of a Promising New Drug for the Treatment of a Life Threatening Disease.

Conference Blood · November 16, 2007 AbstractIntroduction: Veno-occlusive disease (VOD) with multi-organ failure (MOF) has an extremely poor prognosis, with mortality at day (D) +100 after SCT ≥80%. A prior randomized phase 2 study (n=150) comp ... Full text Cite

Analysis of the Cellular Components of the Graft and Clinical Characteristics of 159 Children with Lysosomal and Peroxisomal Disorders (LSD) Undergoing Unrelated Umbilical Cord Blood Transplantation at a Single Center.

Conference Blood · November 16, 2007 AbstractBackground: Allogeneic bone marrow transplantation from related and unrelated donors leads to improvement in longevity and quality of life due to replacement of missing enzyme and engraftment of dono ... Full text Cite

Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study.

Conference Blood · November 16, 2006 AbstractEarly response to therapy, including assessment of MRD is a powerful prognostic factor in childhood ALL. However, there are many other known prognostic factors, and the precise relationship among the ... Full text Cite

Acute Graft Versus Host Disease (GVHD) Is Increased in Patients Receiving Cyclosporine/Cellcept as Frontline Prophylaxis Against GVHD in Pediatric Patients Undergoing Allogeneic Stem Cell Transplantation.

Conference Blood · November 16, 2006 AbstractTraditionally, pediatric patients are prophylaxed against GvHD with cyclosporine (CSA) plus either methotrexate (Mtx) or methylprednisolone (Pred). Mtx worsens the severity of mucositis and renal ins ... Full text Cite

Melphalan Containing Cytoreduction Results in a Good Overall Survival (OS) in Pediatric Patients with Relapse or Refractory AML Undergoing Unrelated Umbilical Cord Blood Transplantation (UCBT).

Conference Blood · November 16, 2006 AbstractChildren with AML unable to achieve remission after initial diagnosis or at relapse will not be cured by conventional therapy but may be salvaged by allogeneic hematopoietic stem cell transplantation ... Full text Cite

Patient controlled analgesia by proxy

Conference Biology of Blood and Marrow Transplantation · February 2006 Full text Cite

Management of cytomegalovirus in the pediatric bone marrow/stem cell transplantation population

Conference Biology of Blood and Marrow Transplantation · February 2005 Full text Cite

Comparison of Diagnostic and Relapse Flow Cytometry Phenotypes in Childhood ALL: Implications for Residual Disease (MRD) Detection.

Conference Blood · November 16, 2004 AbstractFlow cytometric analysis of MRD depends on detecting phenotypically abnormal populations. Phenotypic shifts are known to occur but there is little information to indicate how these shifts affect dete ... Full text Cite

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

Conference Blood · November 16, 2004 AbstractIntroduction: DF, a polydisperse oligonucleotide, has anti-thrombotic, anti-ischemic and thrombolytic properties, especially on microvasculature. Studies have suggested that DF modulates endothelial ... Full text Cite

Unrelated umbilical cord blood transplantation for familial erythrophagocytic lymphohistiocytosis

Conference Biology of Blood and Marrow Transplantation · February 2004 Full text Cite